Header cover image

Hong Kong Pharmaceuticals & Biotech Buy the Dip

UPDATED Aug 11, 2022

Companies which may present a buying opportunity after a dip in share price.

11 companies
CompanyLast Price7D Return1Y ReturnMarket CapAnalysts TargetValuationGrowthDiv Yield
1877Shanghai Junshi BiosciencesHK$31.85-1.5%-35.8%HK$55.8bHK$66.21PS8.2xE116.2%n/a
1801Innovent BiologicsHK$36.502.0%-50.2%HK$54.0bHK$48.75PS10.8xE57.8%n/a
2696Shanghai Henlius BiotechHK$14.92-0.5%-53.2%HK$8.1bHK$26.71PS4.1xE83.7%n/a
6826Shanghai Haohai Biological TechnologyHK$31.902.6%-58.2%HK$15.1bHK$69.23PE15xE20.6%2.6%
570China Traditional Chinese Medicine HoldingsHK$3.20-1.8%-24.2%HK$16.1bHK$4.74PE7.2xE7.3%4.3%
6622Zhaoke OphthalmologyHK$3.100%-61.0%HK$1.7bHK$12.81PB0.6xE68.3%n/a
1952Everest MedicinesHK$16.34-1.6%-74.5%HK$4.8bHK$41.00PS78055.6xE33.6%n/a
6185CanSino BiologicsHK$64.750.08%-78.2%HK$30.8bHK$173.79PE6.7xE11.2%1.4%
15303SBioHK$5.311.1%-28.6%HK$12.9bHK$8.18PE6.7xE6.6%3.7%
1666Tong Ren Tang TechnologiesHK$5.10-2.5%-12.1%HK$6.6bHK$7.69PE11.1xE6.4%3.6%
1643Modern Chinese Medicine GroupHK$0.443.5%-43.6%HK$276.0mn/aPE2.8xn/a3.6%
Page 1 of 1